Conditions: Solid Tumors and Advanced Endometrial Cancer Endometrial Cancer Second-line Treatment VEGF
Keywords: Solid tumors, advanced endometrial cancer, Endometrial Cancer, Second-line treatment, VEGF, Neoplasms, Endometrial Neoplasms, Uterine Neoplasms, Female Genital Neoplasms, Cancer, Carcinoma, Uterine Diseases, Female Genital Diseases, Tumors, Oral Administration, Capsules, Tablets, CHIR258, CHIR-258, CHIR 258, TKI258, TKI-258, TKI 258
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 53
Healthy volunteers: no

Brief summary:
This is a prospective, multi-center, open-label, single-arm, non-randomized, Phase II study to evaluate the efficacy and safety of TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced and/or metastatic endometrial cancer.

Detailed description:

Arms:
arm 1: 1 treatment arm (single agent TKI258), with patients classified into 2 groups based on their FGFR2 mutation status

Interventions: intervention 1: TKI258
Intervention descriptions: intervention 1: None

Protocol document: